![]() This study found that symptom frequency and severity has varied by circulating variant and by vaccination status. ![]() The ZOE COVID Study from the United Kingdom is a comprehensive system that tracks COVID-19 symptoms. To date, there remains no comprehensive list of symptoms that has been validated to have high specificity or sensitivity for COVID-19. Symptoms that are absent at the onset of illness may develop over time with disease progression. Published reports often over-represent individuals who have more severe symptoms, and these may differ across care settings and between different age groups and vaccine statuses. Disease severity and risk factors for severe diseaseĬOVID-19 includes clinical features that present in varying ways with respect to frequency and severity and vary by age, vaccination status and variants of concern.This document is intended to provide clinicians with interim information on currently known clinical features of COVID-19, including signs and symptoms, incubation period, disease severity and risk factors for severe disease and SARS-CoV-2 variants of concern. We should, of course, be cautious about the data from China as it's based on reports, not peer-reviewed evidence yet.The information below is based on currently available scientific evidence and informed by expert clinician opinion, and is subject to change as new information becomes available. BF.7's high R0 might be due in part to a low level of immunity in the Chinese population from previous infection, and possibly vaccination too. We don't know exactly why the situation looks different in China. While the UK Health Security Agency identified BF.7 as one of the most concerning variants in terms of both growth and neutralization data in a technical briefing published in October (it accounted for over 7% of cases at that time), the most recent briefing says BF.7 has been de-escalated due to reduced incidence and low growth rates in the UK. For example, in the US it was estimated to account for 5.7% of infections up to Dec. BF.7 around the worldīF.7 has been detected in several other countries around the world including India, the U.S., the UK and several European countries such as Belgium, Germany, France and Denmark.ĭespite BF.7's immune-evasive characteristics, and worrying signs about its growth in China, the variant seems to be remaining fairly steady elsewhere. BF.7 was resistant to neutralization, driven partly by the R346T mutation. This mutation, which we also see in BF.7's "parent" variant BA.5, has been linked with enhancing the capacity of the virus to escape neutralizing antibodies generated by vaccines or previous infection.Ī recent study examined the neutralization of BF.7 in sera (a component of blood that should contain antibodies) from triple-vaccinated healthcare workers, as well as patients infected during the Omicron BA.1 and BA.5 waves of the pandemic. BF.7 is no different.īF.7 carries a specific mutation, R346T, in the spike protein of SARS-CoV-2 (a protein on the surface of the virus that allows it to attach to and infect our cells). As Omicron has evolved, we've seen the emergence of new subvariants better able to escape immunity from vaccination or prior infection.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |